**IMI OPEN INFO DAY – 3**<sup>RD</sup> **CALL FOR PROPOSALS**

**22 OCTOBER 2010 - SHERATON HOTEL, PLACE ROGIER, BRUSSELS**

**AGENDA**

**MORNING: PLENARY SESSION**

9:30 – 10:30

- Introduction to new IMI projects  
  *Michel Goldman, IMI Executive Director*

- Funding rules and Intellectual Property policy  
  *Magali Poinot, IMI Legal Manager*

10:30 Coffee break

**11:00 – 12:30 ROUND TABLE**

- Round Table: Practical recommendations for applicants, testimonies from IMI project participants:
  - Peter Hecht (IMIDIA), Project Manager, Austria
  - Matthias Gottwald (EMTRAIN, PharmaTRAIN), Bayer Schering Pharma AG, Germany
  - Ferran Sanz (eTOX), IMIM (academia), Spain
  - Laure Masson, IMI IP Working Group, Inserm Transfert, France
  - Anne-Fabienne Weitsch (IMIDIA), Endocells (SME), France

Q&A

12:30 – 13:30: LUNCH BREAK

**INFO BOOTHS – DURING LUNCH AND THROUGHOUT THE AFTERNOON**

- Application procedures
- Funding rules and IP rules
- Project/Consortium management
- Demonstration new IMI Partner Search Tool
### AFTERNOON: PARALLEL WORKSHOPS – 3RD CALL TOPICS

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop 1: Willumsen Room</th>
<th>Workshop 2: Nations I Room</th>
<th>Workshop 3: Rembrandt/Permeke Room</th>
<th>Workshop 4: Nations II Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td><strong>Drug Induced Liver Injury</strong>&lt;br&gt;Presenters: Gerry Kenna, EFPIA Coordinator, Richard Weaver, EFPIA Co-coordinator</td>
<td><strong>Adverse Immune Reactions</strong>&lt;br&gt;Presenter: Daniel Kramer&lt;br&gt;EFPIA topic writer</td>
<td><strong>Tuberculosis</strong>&lt;br&gt;Presenter EFPIA: Martin Pan&lt;br&gt;EPFIA Coordinator</td>
<td><strong>Diabetes</strong>&lt;br&gt;Presenter: Hartmut Ruetten&lt;br&gt;EPFIA Coordinator</td>
</tr>
<tr>
<td></td>
<td>• Improved early prediction of drug induced liver injury (DILI) in man</td>
<td>• Immunogenicity: Assessing the clinical relevance and risk minimization of antibodies to biopharmaceuticals</td>
<td>• Improve the scientific and preclinical models and tools for tuberculosis medicines research</td>
<td>• Personalized medicine in diabetes treatment</td>
</tr>
<tr>
<td></td>
<td>Moderator: Ann Martin</td>
<td>Moderator: Maria Teresa De Magistris</td>
<td>Moderator: Elisabetta Vaudano</td>
<td>Moderator: Fatiha Sadallah</td>
</tr>
<tr>
<td>15:00</td>
<td><strong>Afternoon Coffee Break</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Adverse Immune Reactions</strong>&lt;br&gt;Presenter: Aldo Tagliafico&lt;br&gt;EFPIA Coordinator</td>
<td><strong>Autism</strong>&lt;br&gt;Presenter: Will Spooren&lt;br&gt;EPFIA Coordinator</td>
<td><strong>Public Awareness</strong>&lt;br&gt;Presenter: Fatiha Sadallah, IMI Scientific Manager</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Immunosafety of vaccines – New biomarkers associated with adverse events (early inflammation and autoimmune disease)</td>
<td>• Translational endpoints in autism</td>
<td>• Training programs for the informed patient</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderator: Maria Teresa De Magistris</td>
<td></td>
<td>Moderator: Elisabetta Vaudano</td>
<td>Moderator: Fatiha Sadallah</td>
</tr>
<tr>
<td>16:30</td>
<td><strong>Farewell Coffee</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Innovative Medicines Initiative (IMI)**<br>Postal mail: IMI JU, COV2, Office 14/102 1049 Brussels<br>Visiting address: Covent Garden, Place Rogier 16, 1210 Brussels<br>tel: +32 (0)2-221 81 81 – fax: +32 (0)2-221 81 74<br>email: kim.derijck@imi.europa.eu<br>www.imi.europa.eu